Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kemira Oyj
OMXH:KEMIRA
|
FI |
Phathom Pharmaceuticals Inc
Other Non-Cash Items
Phathom Pharmaceuticals Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Other Non-Cash Items
$41.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Non-Cash Items
$1.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Non-Cash Items
$4.5B
|
CAGR 3-Years
47%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Non-Cash Items
$4.8B
|
CAGR 3-Years
68%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Non-Cash Items
$1B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Non-Cash Items
$4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Phathom Pharmaceuticals Inc
Glance View
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
See Also
What is Phathom Pharmaceuticals Inc's Other Non-Cash Items?
Other Non-Cash Items
41.9m
USD
Based on the financial report for Dec 31, 2025, Phathom Pharmaceuticals Inc's Other Non-Cash Items amounts to 41.9m USD.
What is Phathom Pharmaceuticals Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
42%
Over the last year, the Other Non-Cash Items growth was 17%. The average annual Other Non-Cash Items growth rates for Phathom Pharmaceuticals Inc have been 10% over the past three years , 42% over the past five years .
